



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/529,221

06/30/2006

Bruno Robert

1843.0200001/EKS/AJK

2116

26111

7590

05/21/2009

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 NEW YORK AVENUE, N.W.  
WASHINGTON, DC 20005

EXAMINER

DIBRINO, MARIANNE NMN

ART UNIT

PAPER NUMBER

1644

MAIL DATE

DELIVERY MODE

05/21/2009

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10529221	6/30/06	ROBERT ET AL.	1843.0200001/EKS/AJK

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.  
1100 NEW YORK AVENUE, N.W.  
WASHINGTON, DC 20005

EXAMINER

DiBrino Marianne

ART UNIT	PAPER
1644	20090518

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The communication filed on 2/23/09 is not fully responsive to the communication mailed **1/21/09** for the following reasons: Applicant has failed to elect an ultimate species commensurate with item 4a, i.e., for example, one of the alpha-GalCer antigens recited in one of claims 4 or 6. In addition, Applicant is required to specify if the antibody fragment (not antibody) is fused to the heavy chain (of CD1d) or light chain (b2m) of the CD1d complex. Also, Applicant has not provided an accurate accounting of the claims readable upon the elected species, i.e, for example, Applicant has specified that claims 1-43 and 46-45 read upon the elected species of complexes without costimulatory molecules; however, claim 46 is a withdrawn method claim and claim 45 recites a costimulatory molecule.

Since the response appears to be **bona fide**, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner **Marianne DiBrino**, Art Unit **1644**, whose telephone number is **571-272-0842**.

Marianne DiBrino, Ph.D.

/G.R. Ewoldt/  
Primary Examiner, Art Unit 1644